首页> 外文期刊>The Egyptian Journal of Radiology and Nuclear Medicine >Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience
【24h】

Radioembolization with Yttrium-90 resin microspheres in treatment of HCC with or without PVT: Initial Egyptian experience

机译:使用Yttrium-90树脂微球进行放射栓塞治疗是否伴有PVT的HCC:埃及的初步经验

获取原文
           

摘要

Background/Aim Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. Radioembolization with yttrium-90 (Y-90) microspheres is a new concept in radiation therapy for HCC. The aim of this study is to evaluate efficacy, side effects, and future direction of Y-90 therapy, using TheraSphere?, in patients with HCC with or without PVT. Patients and methods Forty patients were presented by hepatocellular carcinoma most of them with portal vein thrombosis and were treated with Y-90 resin microspheres (SIR-TeX?). Results At one month after treatment the overall response (complete or partial response) was exhibited by 9% of patients, stable disease exhibited by 80% of patients, progressive disease seen in 11% of patients. Conclusion Radioembolization with Y-90 resin microspheres offers a favorable risk/benefit profile for patients presenting with locally advanced unresectable HCC with or without PVT and good liver function.
机译:背景/目的肝细胞癌(HCC)是最常见的肝脏原发性恶性肿瘤。钇90(Y-90)微球体的放射栓塞是HCC放射治疗的新概念。这项研究的目的是评估使用TheraSphere?对患有或不患有PVT的HCC患者进行Y-90治疗的疗效,副作用和未来方向。患者和方法40例肝细胞癌患者均以门静脉血栓形成,并接受Y-90树脂微球(SIR-TeX?)治疗。结果在治疗后一个月,9%的患者表现出总体反应(完全或部分反应),80%的患者表现出稳定的疾病,11%的患者表现出进行性疾病。结论Y-90树脂微球的放射栓塞治疗对局部晚期不可切除的HCC伴或不伴PVT且肝功能良好的患者提供了有利的风险/获益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号